华东医药(000963.SZ)：迈华替尼片上市申请尚在审评审批过程中，有望于年底前获批

Group 1 - The core point of the article is that Huadong Medicine's application for the marketing approval of Maihua Tini tablets is still under review and is expected to be approved by the end of the year [1] - The specific timing of the new drug review and approval process remains uncertain, and the final outcome will depend on the announcements from the National Medical Products Administration (NMPA) and the company [1]